Cross Atlantic Commodities Inc Signs Agreement To Market Snorenz(R)
FT. LAUDERDALE, FL, Oct. 19 /PRNewswire-FirstCall/ -- Cross Atlantic Commodities, Inc. (CXAC.PK), a successful manufacturer of specialty health and beauty products, announced signing a distribution agreement with the holders of the Snorenz patent. Snorenz(R) is a nationally well known snoring product.
"We have done our homework on Snorenz(R) and are very excited about the research that the previous company has done and the size of the snoring category", states Jorge Bravo President / CEO. In 2002, the Company completed a double blind study at Northwestern Hospital's Sleep Center in Atlanta, GA, under the direction of Dr. Samuel Mickelson of the Advanced Ear Nose and Throat P.C. The results of that study concluded that SNORenz(R) is an effective product to reduce the noise associated with snoring. We will begin marketing Snorenz, first through Online Marketing, Pay Per Search and Affiliate Marketing Programs. Within the next few weeks our new Snorenz website will be live.
